Extrahepatic Cholangiocarcinoma: Durvalumab with Radiofrequency Ablation

We are studying a new treatment combining durvalumab and radiofrequency ablation for patients with bile duct cancer. The goal is to see if this combination improves effectiveness and safety compared to standard therapies.

>2 years >20 visits Efficacy phase (II)No Placebo Standard Medicines InjectionGastroenterologyOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Imfinzi

Imfinzi is a cancer medicine that helps the immune system find and fight tumor cells.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Cisplatin

Cisplatin is a substance used in chemotherapy to kill or stop the growth of cancer cells.

Durvalumab

Durvalumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein tumors use to hide.

Gemcitabine

Gemcitabine is a substance that slows or stops cancer cell growth and is used to treat several cancers, including pancreatic and lung.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Universitaetsklinikum Bonn AöR

Medizinische Klinik und Poliklinik I

Bonn, Germany

Universitaetsklinikum Duesseldorf AöR

Klinik für Gastroenterologie, Hepatologie und Infektiologie

Düsseldorf, Germany

Krankenhaus Nordwest GmbH

Institut für Klinisch-Onkologische Forschung

Eschborn, Germany

Sponsor: Institut fuer Klinische Krebsforschung IKF GmbH

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.